The Female Body and Menopause – Ways to Alleviate Unwanted Symptoms

The term "perimenopausal transition" is frequently—and incorrectly—used interchangeably with "menopause" in everyday language, yet it specifically refers to the multi-year precursor phase leading up to the permanent cessation of menstruation. A defining characteristic of this transitional period is the extensive hormonal fluctuations occurring within a woman’s body, which progressively diminish fertility. The climacteric, encompassing the entirety of reproductive senescence, is conventionally divided into three distinct stages: **1. Premenopause**, typically commencing around **age 41**, serves as the initial phase preceding true menopause and is often accompanied by menstrual irregularities; **2. Perimenopause**, generally occurring between **ages 45 and 46**, represents the immediate preparatory phase for menopause; **3. Postmenopause**, beginning after the final menstrual period—usually between **ages 50 and 52**—and persisting for the remainder of life, signifies the irreversible termination of both reproductive capacity and menstrual bleeding. Menopause, therefore, constitutes the physiological endpoint of aging-related hormonal shifts, resulting in the permanent cessation of ovarian function and the menstrual cycle.

Menopause represents a natural life stage for women characterized by profound alterations in endocrine regulatory mechanisms, thereby triggering a cascade of complex adaptive responses across multiple bodily systems. These hormonally driven transformations significantly impact not only physical health but also psychological and social functioning, often necessitating adjustments to established lifestyle patterns.

Menopause represents a critical transitional period in a woman’s life, characterized by a gradual, physiologically determined decline in the synthesis of sex hormones. This process is primarily associated with the cessation of ovarian function, resulting in a substantial reduction in the secretion of both estrogens and progesterone—two key regulators of the menstrual cycle. The ultimate consequence of these hormonal shifts is the permanent cessation of menstruation, which stands as one of the defining clinical manifestations of menopause. It is equally important to note that this phase is accompanied by a decrease in androgen production, including testosterone, which in turn leads to observable alterations in sexual function. Symptoms may include diminished libido, reduced responsiveness to erotic stimuli, and a decline in the intensity or quality of orgasmic experience.

The hormonal imbalance extends beyond behavioral dimensions, also yielding significant anatomical consequences. A common manifestation is heightened sensitivity and fragility of intimate tissue, which can result in painful intercourse—a condition medically termed dyspareunia. This symptom frequently co-occurs with progressive vaginal atrophy, characterized by the thinning and loss of elasticity in mucosal tissues. As demonstrated in research by Stec et al. (2014), these atrophic changes predispose individuals to inflammatory conditions and bacterial or fungal infections. These findings are further corroborated by Bakalczuk et al. (2005), who emphasize an increased susceptibility to genital tract infections during the postmenopausal period.

The transition through perimenopause and menopause represents a substantial challenge to emotional balance and psychological well-being for a significant proportion of the female population. A comprehensive survey involving 300 women aged 40–65 revealed that 42% of postmenopausal participants exhibited symptoms consistent with mild anxiety disorders, whereas 32% demonstrated indicators of mild depressive episodes (source: Koligat D. et al., 2015). Furthermore, the phenomenon of hypoestrogenemia—characterized by chronic estrogen deficiency—extends far beyond the reproductive system, exerting a multifaceted impact on overall physiological function. Researchers emphasize that diminished levels of these hormones constitute a major risk factor for the development of various metabolic and cardiovascular conditions, including: the progression of atherosclerotic lesions, insulin resistance, arterial hypertension, coronary artery disease, and dysregulation of glucose metabolism (based on: Grycewicz J., Cypryk K., 2008).

Hormonal imbalances associated with the menopausal transition contribute to an upward trend in overall body mass alongside an accumulation of intra-abdominal—commonly referred to as visceral—adipose tissue. Concurrently, there occurs a progressive decline in lean body mass, encompassing reductions in muscle tissue and other non-fat components. As documented in the research conducted by B. L. Wajchenberg (2000), a substantial proportion of women both during the menopausal phase and in the postmenopausal years encounter challenges related to excessive body weight, frequently progressing to a clinical diagnosis of obesity.

Dysfunctions of the circulatory system frequently emerge as a direct sequela of physiological transformations accompanying the menopausal transition. Elevated biosynthesis of unsaturated fatty acids, dysregulation of lipid profiles, impaired glucose utilization by the organism, and excessive adiposity constitute merely a segment of the etiopathogenetic spectrum. It is critical to emphasize that diminished estrogen concentrations stimulate collagen fiber proliferation within vascular walls, thereby augmenting their rigidity (as demonstrated by Kublickiene et al., 2005). These structural alterations consequently decelerate blood flow, which may precipitate episodic migraine headaches—corroborated by Ripa and colleagues’ 2015 analysis.

It is essential to emphasize that menopause is associated not only with declining estrogen levels but also with a deficiency in progesterone, which may result in significant regulatory dysfunctions. Insufficient concentrations of this hormone disrupt the proper operation of the hypothalamus—a critical brain region responsible for maintaining hormonal balance—and impair signaling within the GABAergic system. Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system, exerts a relaxing effect on muscle tissue and a calming influence on cognitive processes, including the facilitation of sleep onset and the maintenance of sleep continuity. Dysregulation within this system, in turn, may predispose individuals to emotional instability, manifesting as heightened irritability, depressive mood states, or even feelings of helplessness in response to daily challenges. This phenomenon has been documented in research, including studies by Klein (2003), thereby confirming its clinical significance.

It is unequivocally established that the array of symptoms accompanying the menopausal transition substantially compromises psychophysical well-being, thereby impairing both personal and occupational functionality. Rigorous scientific analysis demonstrates a clear inverse correlation between the severity of menopausal symptomatology and the likelihood of women maintaining full-time employment, with psychological manifestations—such as anxiety, mood lability, and cognitive disturbances—exerting a disproportionately greater adverse effect on workforce participation than vasomotor symptoms (e.g., hot flashes), as evidenced by Bryson et al.’s 2022 meta-analysis. To quantify the occupational ramifications, one may examine the findings of a large-scale survey involving 4,440 women aged 54–58 (Faubion et al., 2023), which revealed that 13.4% of respondents attributed at least one adverse workplace outcome—ranging from interpersonal conflicts to reduced productivity or procedural errors—to their menopausal symptoms. Furthermore, 10.8% reported sickness-related absences within the past year due to symptom exacerbation, with an average duration of three working days. Critically, the study identified a linear relationship wherein escalating symptom severity corresponded to an increased probability of occupational errors, posing significant risks to both individual career trajectories and organizational efficiency. These data underscore an urgent imperative for systemic interventions that address menopausal health through integrated workplace policies—such as adaptive scheduling, targeted wellness programs, and ergonomic accommodations—to mitigate the multifaceted impacts on professional performance and overall quality of life.

Menopause represents a natural, biologically determined transition in every woman’s life, yet its associated symptoms—including hot flashes, sleep disturbances, and mood fluctuations—can significantly diminish day-to-day well-being. Through carefully selected strategies encompassing both lifestyle adjustments and pharmacological interventions, it is possible to mitigate these discomforts and sustain a fulfilling quality of life during this phase.

A strategic dietary modification involves incorporating plant-based foods rich in phytoestrogens—biologically active compounds whose molecular structure and functional properties closely mimic those of human estrogens. This nutritional approach is frequently advised for women experiencing menopausal transitions, as well as individuals managing conditions such as bone density loss (osteoporosis) or mammary carcinomas. Primary natural sources of these compounds include leguminous seeds, with particular emphasis on soybeans and their derivatives—such as tofu, tempeh, and soy-based beverages. Empirical evidence from clinical research confirms that consistent phytoestrogen intake exerts beneficial effects on the urinary and reproductive systems. A comprehensive review of 33 randomized controlled trials (Abdi et al., 2021) demonstrated that diverse delivery methods—ranging from topical gels and intimate-area creams to oral capsules containing standardized botanical extracts—effectively mitigate urogenital symptoms. The studied plants included fennel (Foeniculum vulgare), kudzu root (Pueraria mirifica), soybean (Glycine max), and hops (Humulus lupulus), the latter of which exhibits particularly strong binding affinity to estrogen receptors due to its high concentration of 8-prenylnaringenin.

Structured physical exercise serves as a cornerstone for supporting women during menopause and perimenopause, offering measurable benefits in alleviating troublesome symptoms. Clinical evidence demonstrates that a 12-week exercise regimen can substantially diminish the frequency of hot flashes, enhance sleep quality, and markedly reduce joint discomfort. Notably, these improvements are most pronounced in postmenopausal women and those in the perimenopausal phase, whereas premenopausal individuals may derive less benefit from certain activities, such as yoga. Furthermore, pelvic floor muscle training has been shown to be highly effective in reducing episodes of urinary incontinence, as documented in meta-analyses involving thousands of participants. The integration of physical activity with phytoestrogen supplementation may represent a comprehensive strategy for mitigating menopausal symptoms and improving daily functioning—particularly in occupational settings, where such symptoms can significantly impair performance.